Brief: Onxeo Announces Positive Interim Results From Phase 1 Study Of AsiDNA

Valerio Therapeutics SA

05/11/2018 06:14

Nov 5 (Reuters) - ONXEO SA  C4X.PA :
    * ONXEO ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1
STUDY OF
ASIDNA, A FIRST-IN-CLASS DNA DAMAGE RESPONSE INHIBITOR
    * ROBUST BIOLOGICAL TARGET ENGAGEMENT IN PATIENT TUMOR CELLS
CONFIRMS ACTIVITY OF ASIDNA WHEN ADMINISTERED INTRAVENOUSLY
    * INTENDS TO EXPAND ASIDNA CLINICAL PROGRAM IN COMBINATION
IN
TARGETED INDICATIONS AS SOON AS H1 2019
    * FAVORABLE SAFETY PROFILE WITH NO DRUG-RELATED SERIOUS
ADVERSE
EVENT AND NO DOSE-LIMITING TOXICITY
    * ADMINISTRATION OF DL4 (900MG) IS ONGOING AND FULL DATA SET
FROM
DRIIV-1 IS EXPECTED TO BE AVAILABLE IN FIRST HALF OF 2019

Source text for Eikon:  ID:nNDL3WsT93 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))